阳离子两亲性H1-抗组胺剂在临床前研究中已显示出抗肿瘤效果。我们进行了一项回顾性队列研究，以调查它们对胰腺腺癌（PDAC）患者的影响。我们使用年龄、性别和癌症分期等标准，在台湾的两家三级医疗中心进行了一项配对队列研究。主要结局为总生存期（OS），次要结局为无进展生存期（PFS）和客观缓解率（ORR）。我们将28名阳离子两亲性抗组胺药物用户与56名非阳离子两亲性抗组胺药物用户进行了配对。与非用户相比，阳离子两亲性抗组胺药物用户的OS显著延长（中位数16.4 [IQR，2.8 - 89.0] vs. 5.8 [IQR，2.0 - 9.8] 个月；p<0.001）并且PFS显著延长（中位数12.2 [IQR，2.2 - 83.3] vs. 5.2 [IQR，1.7 - 8.4] 个月；p=0.002）。在Cox比例风险模型中，使用阳离子两亲性抗组胺药物与全因病死率和疾病进展的风险约为60%较低。此外，阳离子两亲性抗组胺药物用户的ORR显著高于非用户（39% vs. 7%，p=0.004）。我们的研究表明，阳离子两亲性抗组胺药物与PDAC患者的生存结局有关。© 2023. 作者（以独家许可的身份）许可给Springer Science+Business Media, LLC，是Springer Nature的一部分。

Cationic amphiphilic H1-antihistamines have demonstrated antitumor effects in preclinical studies. We conducted a retrospective cohort study to investigate their impact on patients with pancreatic adenocarcinoma (PDAC).We performed a matched cohort study involving PDAC patients from two tertiary centers in Taiwan using criteria including age, sex, and cancer stage. The primary outcome was overall survival (OS), and the secondary outcomes were progression-free survival (PFS) and objective response rates (ORR).We matched 28 cationic amphiphilic antihistamine users with 56 non-cationic amphiphilic antihistamine users. Cationic amphiphilic antihistamine users showed significantly longer OS (median 16.4 [IQR, 2.8 - 89.0] vs.5.8 [IQR, 2.0 - 9.8] months; p<0.001) and PFS (median 12.2 [IQR, 2.2 - 83.3] vs. 5.2 [IQR, 1.7 - 8.4] months; p=0.002) compared to non-users. In the Cox proportional hazard models, the use of cationic amphiphilic antihistamines was associated with approximately 60% lower risk of all-cause mortality and disease progression. Additionally, cationic amphiphilic antihistamine users exhibited a significantly greater ORR than non-users (39% vs. 7%, p=0.004).Our study suggests that cationic amphiphilic antihistamines are associated with improved survival outcomes in PDAC patients.© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.